Adverse event monitoring and reporting is essential given the investigational nature of BPC-157 and limited human safety database
Non-GLP-1 Medications: The platform also describes access to non-GLP-1 options including Contrave (bupropion-naltrexone), metformin , topiramate , and zonisamide - medications that target different mechanisms related to appetite, cravings, blood sugar regulation, and metabolic function
On the other hand, research shows that people who practice stress management techniques during their weight loss journey tend to lose more weight
Our team works directly with your insurer to access available coverage, manufacturer discounts, and copay assistance programs
In clinical trials, GLP-1 drugs given in higher dosages than for diabetes showed the ability to stimulate double-digit-percentage weight loss in patients